A Systematic Study on the Optimal Nucleotide Analogue Concentration and Rate Limiting Nucleotide of the SARS-CoV-2 RNA-Dependent RNA PolymeraseSARS-CoV-2 RNA 의존성 RNA 중합효소의 최적 뉴클레오티드 유사체 농도 및 속도 제한 뉴클레오티드에 대한 체계적인 연구Article Published on 2022-07-272022-09-11 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 치료제, [키워드] adenosine analogue Antiviral compounds antiviral efficacy approved assays clinically competition complex Concentration condition cordycepin coronavirus COVID-19 COVID-19 pandemic COVID-19 treatment drug effective Efficiency EIDD-2801 element GS-443902 GS-5734 GTP in vitro new SARS-CoV-2 NUC-7738 nucleoside nucleotide nucleotides physiological Rate RdRP Remdesivir Repurposed drug RNA RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 RdRp SARS-CoV-2 replication sensitivity the SARS-CoV-2 Treatment [DOI] 10.3390/ijms23158302 PMC 바로가기 [Article Type] Article
Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster modelMolnupiravir는 햄스터 모델에서 Omicron을 포함한 SARS-CoV-2 변이체를 억제합니다Article Published on 2022-07-082022-09-11 Journal: JCI Insight [Category] COVID19(2023년), SARS, 변종, [키워드] Administered Adults Alpha Analysis Antiviral approved Beta caused COVID-19 Delta VOC delta VoCs demonstrated drug drug therapy effective Efficacy examined hamster hamsters Histopathologic analysis identify infectious titer infectious titers inhibit inhibited inhibitory effect Lower respiratory tract lung Lung disease Lungs Measures mechanism molnupiravir mouse Mouse models mutagenic mutated nucleoside omicron Preexisting immunity reduction in Replication SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 lineage SARS-CoV-2 variant SARS-CoV-2 variants Spike protein the SARS-CoV-2 Treatment upper and lower respiratory tract variant Viral antigen viral RNA genome Virology virus replication VoC VOCs was reduced [DOI] 10.1172/jci.insight.160108 PMC 바로가기 [Article Type] Article
The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling항바이러스 치료의 표적으로서의 SARS-CoV-2 헬리카제: in silico 모델링을 통한 잠재적인 소분자 억제제 식별Article Published on 2022-07-012022-09-11 Journal: Journal of molecular graphics & modelling [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] Acetylcysteine active site acute respiratory syndrome addition anti-inflammatory property Antiviral antiviral activity antiviral therapeutics antivirals binding free energy clavulanic acid Compound coronavirus coronavirus disease COVID-19 DHX9 DNA DNA2 expected Fatty acid fatty acids free energies Helicase Hepatitis hepatitis C highlighting identification identify in silico include inhibitor inhibitory activity initial lead leads Ligand MERS-CoV molecular dynamics Molecular dynamics simulation molecular dynamics simulations non-structural protein nsp13 nucleoside performed reported Research respiratory SARS-CoV SARS-CoV-2 SARS-CoV-2 nsp13 selected sequence Severe acute respiratory syndrome small molecule inhibitor specific inhibitor specific inhibitors strain structural homology structural proteins Structure structures synthetic the SARS-CoV-2 utilised Vaccine variant was performed were used [DOI] 10.1016/j.jmgm.2022.108193 PMC 바로가기 [Article Type] Article
PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID-19 patientsPF-07321332(니르마트렐비르)는 인간 ENT1 또는 ENT2와 상호작용하지 않음: COVID-19 환자에 대한 시사점Article Published on 2022-07-012022-09-11 Journal: Clinical and translational science [Category] COVID19(2023년), SARS, 치료제, [키워드] acute lung injury antivirals bind Biotransformation Clinical efficacy clinical trials contribute coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death downregulation drug Efficacy EIDD-1931 Emergency use authorization Endothelial cell ENT ENTs expression Factor FDA food greater hypoxia in vitro inhibitor Interaction investigated lung epithelial Lung injury Lungs metabolite molnupiravir Nirmatrelvir nucleoside nucleoside analog nucleoside analogs pandemic Patient patients with COVID-19 PF-07321332 protease Protease inhibitor reflected Remdesivir Replication repression SARS-CoV-2 Severe acute respiratory syndrome shown substrate substrates the SARS-CoV-2 undergo unlikely US Food and Drug Administration viral replication Viral RNA Virology [DOI] 10.1111/cts.13292 PMC 바로가기 [Article Type] Article
Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats임신한 쥐에서 항바이러스성 렘데시비르와 주요 대사산물인 GS-441524의 생체변환 및 태반 전이Article Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] 치료제, [키워드] amniotic Amniotic fluid Anti-viral approved AUC Biotransformation Blood Blood-placental barrier C max coronavirus disease Coronavirus disease 2019 COVID-19 cross during pregnancy evaluated fetus GS-441524 Hypothesis Liquid chromatography mass spectrometry maternal blood metabolite Microdialysis MONITOR mother multisite nucleoside parameter pharmacokinetic pharmacokinetics Placenta placental barrier predominant Pregnancy pregnant RATs Remdesivir Science shown Taiwan Tandem mass spectrometry technology tissues transfer treat Treatment UHPLC was used while [DOI] 10.1016/j.ebiom.2022.104095 PMC 바로가기 [Article Type] Article
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infectionGS-441524의 정맥내 전달은 SARS-CoV-2 감염의 아프리카 녹색 원숭이 모델에서 효과적입니다Article Published on 2022-07-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus administration African African green monkey African green monkeys AGM AGMs alveolar antiviral activity antiviral efficacy antiviral therapy approved assays causative agent coronavirus COVID-19 COVID-19 pandemic determine dose dose-dependent efficacy dosed exhibit FDA green green monkey GS-441524 in vitro in vivo intravenous less Lower respiratory tract lung nucleoside oral bioavailability parent nucleoside plasma plasma concentration plasma concentrations potential therapies potential therapy primary cells RDV reduced reduction Remdesivir required respiratory virus respiratory viruses resulting SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significant reductions significantly higher Support treated Treatment treatment of COVID-19 triphosphate [DOI] 10.1016/j.antiviral.2022.105329 PMC 바로가기 [Article Type] Article
The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2뉴클레오사이드/뉴클레오타이드 유사체 테노포비르와 엠트리시타빈은 SARS-CoV-2에 대해 비활성입니다Article Published on 2022-06-302022-09-11 Journal: Molecules [Category] COVID19(2023년), SARS, 치료제, [키워드] accelerated active site acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antiviral activity antiviral agent Antiviral agents Antiviral effect approaches approved approved drug biochemical causative pathogen caution Cell clinicians and researcher Concentration coronavirus COVID-19 COVID-19 pandemic demonstrated Efficiency emtricitabine epithelial FTC HIV-1 HIV-1 NRTI human lung in vitro data inactive indicate inhibitor lack metabolite NHBE NTP nucleoside polymerase Prevent RdRP RdRp active site required reverse transcriptase RNA polymerase SARS-CoV-2 SARS-CoV-2 RNA severe acute respiratory syndrome Coronavirus TAF TDF tenofovir Tenofovir alafenamide the SARS-CoV-2 transcriptase treat unlikely [DOI] 10.3390/molecules27134212 PMC 바로가기 [Article Type] Article
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants렘데시비르와 GS-441524는 델타, 오미크론 및 기타 신종 SARS-CoV-2 변이체에 대해 항바이러스 활성을 유지한다Article Published on 2022-06-212022-09-11 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] 50% effective concentration activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antiviral antiviral activity Antiviral agents Antiviral treatment change circulating Combination conserved coronavirus COVID-19 Delta disease severity Effectiveness ELISA enzyme-linked immunosorbent enzyme-linked immunosorbent assay Evidence evidence of exhibited fold Genetic variation GS-441524 highlight isolate Neutralizing antibodies Nsp12 nucleoside omicron Omicron variants Other P323L pandemic parent nucleoside potency predominant prevalent RdRP RDV reduction remained Remdesivir retained RNA-dependent RNA polymerase SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sequence sequences severe acute respiratory syndrome Coronavirus Spread Substitution Support susceptible sustained tested the SARS-CoV-2 Treatment Vaccine variant variants Variation Veklury Viral transmission virus viruses WA1 [DOI] 10.1128/aac.00222-22 PMC 바로가기 [Article Type] Article
A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies투과성 연구에서 나노제형을 사용하여 적용된 COVID-19 약물 몰누피라비르의 측정을 위한 안정성을 나타내는 RP-HPLC 방법Article Published on 2022-05-302022-09-11 Journal: Journal of pharmaceutical and biomedical analysis [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 antiviral drugs applied Caco-2 calculated candidate cell line column conditions Coronavirus-2 Council COVID-19 demonstrated drug drug candidate drug delivery system flow rate homogeneity ICH in vitro Infection linear molnupiravir N4-hydroxycytidine nucleoside optimization oxidative stress pandemic peak permeability prodrug quantitation robust RP-HPLC SARS-CoV-2 SARS-CoV-2 treatment selective Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus specificity stability validation was performed was used water [DOI] 10.1016/j.jpba.2022.114693 PMC 바로가기 [Article Type] Article
Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase ComplexReview Published on 2022-05-032023-07-02 Journal: Molecules [Category] COVID19(2023년), SARS, [키워드] coronavirus ExoN exonuclease inhibitor nsp14 nucleoside polymerase Proofreading SARS-CoV-2 [DOI] 10.3390/molecules27092918 PMC 바로가기 [Article Type] Review